RecruitingPhase 4NCT06577493
Effectiveness of Phenazopyridine for Pain Following Urodynamics
Sponsor
University of South Florida
Enrollment
66 participants
Start Date
Dec 17, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of the study is to determine if taking phenazopyridine (AZO) at the time of urodynamic study testing will decrease pain experienced by patients after undergoing urodynamic testing.
Eligibility
Sex: FEMALEMin Age: 18 YearsMax Age: 99 Years
Inclusion Criteria5
- ability to provide informed consent
- ability to complete visual analog scale
- requiring urodynamic testing
- years of age or older
- must be able to read and write in English or Spanish
Exclusion Criteria10
- allergy to phenazopyridine
- a urinary tract infection in the prior 2 weeks
- women who did not undergo urodynamic testing
- patient less than 18 years old
- patients with known (noted in patient chart and verbally asked) severe renal insufficiency with GFR <50 mL/min,
- patients with known (noted in patient chart and verbally asked) severe hepatitis
- patients with known (noted in patient chart and verbally asked) G6PD deficiency
- history of fibromyalgia
- history of interstitial cystitis
- non English or Spanish speaking
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGPhenazopyridine Hydrochloride 99.5 MG
Experimental arm to take two 99.5 mg phenazopyridine hydrochloride by mouth for a total of 199mg immediately prior to start of urodynamic testing
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06577493